InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,749.16
(
0.77%
)
US TECH 100
19,573.20
(
1.13%
)
Dow Jones
42,172.97
(
0.98%
)
Brent Oil
73.31
(
-0.95%
)
Bitcoin
70,007.88
(
-0.29%
)
Post# of 7234
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Frankestin

Send PM Follow Ignore
Followers 8
Posts 1934
Boards Moderated 0
Alias Born 09/10/2012

Frankestin

Re: None

Thursday, 11/03/2022 12:28:07 PM

Thursday, November 03, 2022 12:28:07 PM

Post# of 7234
made the due proportions...
INCY
Jakafi’s (a first-in-class JAK1/JAK2 inhibitor approved for polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease) revenues came in at $619.5 million.
Jakafi® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up